Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel
Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.
Developing immuno-oncology therapies for patients in need
The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.
We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.About Coherus Immuno-oncology